Starting Wegovy at 1.7mg: what this dose actually means for you

Why does the schedule land on 1.7mg specifically?

The Wegovy titration pathway exists for one reason: to give your digestive system time to adapt to semaglutide before the dose climbs higher. Nausea, in particular, tends to be dose-dependent — it peaks in the days after an increase and then settles. The 1.7mg step is the bridge between the mid-range doses and 2.4mg, which is where the STEP 1 trial, published in the New England Journal of Medicine, recorded an average body-weight reduction of around 15% over 68 weeks. That landmark figure came from the 2.4mg maintenance dose, not 1.7mg. The 1.7mg rung exists to make the final step safer, not to be a therapeutic plateau.

The gap between 1.0mg and 1.7mg is the widest in the whole schedule. Some people breeze through it; others find the jump noticeable. That's not a sign anything is wrong — it's exactly why the schedule builds in a full four weeks at each level before moving on. Your prescriber, not the calendar, decides the right moment to proceed. If you have questions about earlier steps in the plan, the Wegovy starting dose page explains how the schedule begins and why pace matters from day one. For a closer look at how those early weeks typically unfold, the guide to starting Wegovy at 0.5mg covers what to expect at the very first dose, and the page on starting Wegovy at 1mg explains what changes when you reach that first step up.

What tends to happen to side effects at this point in the schedule?

If you got through 1.0mg without much trouble, 1.7mg may feel similar after the first few days. If GI symptoms were still present at 1.0mg, expect them to return briefly, typically peaking in the first week of the new dose and easing by week two or three. The most commonly reported effects at this stage are nausea, loose stools or constipation, reflux and a feeling of fullness that can make it hard to eat normal-sized meals. Fatigue and mild headaches are reported too, especially in the first week.

Staying well hydrated matters more than people expect. When appetite drops sharply, it's easy to forget fluids. Eating smaller portions slowly, choosing protein-rich foods and avoiding very fatty or spicy meals during the adjustment window all help manage GI discomfort in practice. If symptoms feel severe, persistent or include pain that reaches through to your back, contact a healthcare professional promptly, the MHRA's Yellow Card scheme is also available for reporting any suspected side effects from your medicine. Symptoms like that should never be waited out.

The full Wegovy doses guide covers the broader side-effect picture across the entire titration range, which can be useful context if you're comparing notes with friends or partners on the same treatment.

How does appetite suppression change as you move through the higher doses?

Most people notice that the effects on hunger become more consistent, rather than just blunting appetite, 1.7mg and above tend to reduce food noise more reliably through the day. That shift can feel like a relief after weeks of the medicine feeling variable. It can also catch people out: forgetting to eat enough protein, or drinking too little, becomes a real pattern at this stage and is worth monitoring deliberately.

Appetite suppression this strong can also bring some psychological adjustment. If you've spent years thinking about food a lot, its sudden absence is sometimes disorienting rather than purely welcome. That's a more common experience than many people expect, and it's worth mentioning to your prescriber rather than treating it as something to push through alone.

For context on how 1.7mg compares to the final step, the 2.4mg dose page explains what the maintenance phase looks like and what the clinical evidence says about results at that level. If you're considering the broader treatment picture, the Wegovy overview covers licensing, eligibility and how the medicine fits into a wider weight-management plan.

What should you tell your prescriber before moving from 1.7mg to 2.4mg?

Before any dose increase a prescriber needs an honest picture of the past four weeks: how your appetite has changed, what side effects appeared and whether they've settled, whether your weight has shifted, and whether anything else has changed in your health or medicines. This is especially relevant if you take oral contraceptives, for tirzepatide there's a specific interaction concern, but for semaglutide the NHS does not flag the same reduced-absorption risk. Still, your prescriber should know your full medicines list at every review.

The review before stepping to 2.4mg is a proper clinical conversation, not a formality. At nume (sorry, at our pharmacy) every dose increase goes back to a GPhC-registered prescriber who reads your case notes before authorising anything. If 1.7mg is still causing significant symptoms, staying at this dose a little longer is always an option; the goal is a sustainable progression, not a fast one. If you want to explore what a structured private treatment pathway looks like, the treatment consultation page sets out how the process works from the start.